Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03924076
Other study ID # KE/FK/293/EC/2018
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 14, 2018
Est. completion date April 4, 2019

Study information

Verified date April 2019
Source Gadjah Mada University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is aimed to determine effect of paraprobiotic Lactobacillus plantarum IS-10506 on humoral immune response by measuring faecal sIgA and blood IgG, IgM, and IgA


Description:

The type of the study is double blind randomize placebo-controlled trial with minimum 72 subjects which divided into 2 groups i.e. 1) placebo group which will receive UHT milk (125 mL) and 2) treatment group which will received UHT milk + paraprobiotic Lactobacillus plantarum IS-10506 5 x 1010 CFU/day (125 mL). The subjects have to consume one pack of milk every day for 90 consecutive days. Before and after intervention (day 30 and day 90), several data will be collected i.e. faecal sIgA, blood IgG, IgM, and IgA. The subjects recruited from elementary school in Yogyakarta District.


Recruitment information / eligibility

Status Completed
Enrollment 79
Est. completion date April 4, 2019
Est. primary completion date January 4, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 7 Years to 9 Years
Eligibility Inclusion Criteria:

- children at age of 7-9 years

- have normal body mass index (BMI) i.e. -2 = z-score < +1, slightly overweight z-score < +1.5, and slightly underweight z-score > -3.

Exclusion Criteria:

- allergic to milk

- consuming other probiotic product

- he/she do not want to stop consumption & doing washout for 2 weeks.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
UHT Milk + Lactobacillus plantarum IS-10506
125 ml UHT milk (+Lactobacillus plantarum IS-10506) given to treatment group
UHT Milk
125 ml UHT milk given to placebo group

Locations

Country Name City State
Indonesia Universitas Gadjah Mada Sleman D.I.Yogyakarta

Sponsors (1)

Lead Sponsor Collaborator
Gadjah Mada University

Country where clinical trial is conducted

Indonesia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Serum IgG Measuring IgG (ng/mL) in collected serum 90 days
Primary Serum IgA Measuring IgA (ng/mL) in collected serum 90 days
Primary Serum IgM Measuring IgM (ng/mL) in collected serum 90 days
Primary Faecal sIgA Measuring sIgA (ng/mL) in collected feses 90 days
Secondary Weight Measuring weight (kg) change 90 days
Secondary Height Measuring height (cm) change 90 days
See also
  Status Clinical Trial Phase
Completed NCT03164967 - Study to Evaluate Safety and Pharmacokinetics of BIVIGAM® in Primary Immune Deficiency Subjects Aged 2 to 16 Phase 4